 A double-blind neither the patient nor the physician know the name of the study drug, 6-month, multicenter, placebo-controlled trial to evaluate the combination of galantamine with nimodipine in patients with mixed dementia on cognition and quality of life. The target dose of galantamine is 24 mgday and nimodipine will be taken in fixed doses of 90 mgday. Primary outcomes will be measured by a computerized battery of neuropsychological tests and Quality of Life QoL scores. Secondary outcomes will be measured by ADAS-cog, Clinical Global Impression CGI and Neuropsychiatric Inventory NPI. Mixed dementia Alzheimers Disease AD associated with cerebrovascular disease is one of the most common causes of dementia, which remain largely underdiagnosed. Little is known about specific treatments for this condition. Ischemic lesions by themselves seem to play an important role in cognitive impairment, even in the presence of AD pathology. Hypotheses: - Galantamine 16-24 mgday in combination with nimodipine 90 mgday is superior to galantamine monotherapy 16-24 mgday in improving or stabilizing cognition in patients with AD associated with cerebrovascular disease mixed dementia, as measured by the CNTB at 6 months. - Galantamine 16-24 mgday in combination with nimodipine 90 mgday is superior to galantamine monotherapy 16-24 mgday on QoL measures in this population as measured by QoL - AD at 6 months. Group 1: galantamine oral 8mgday for a month, 16mgday for 4 weeks and after 24mgday until end of study plus nimodipine oral 30mg tid during all study. Group 2: Group 1: galantamine oral 8mgday for a month, 16mgday for 4 weeks and after 24mgday until end of study plus placebo oral 30mg tid during all study. 